Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifapentine (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of Risk

NCT02735590 is registered in ClinicalTrials.gov with University of Cape Town as lead sponsor.

NCT NCT02735590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02735590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifapentine (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of Risk
Lead sponsor
University of Cape Town
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 20, 2016
Completion date
December 31, 2019
Enrollment
2,927 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis